N/A
Manufactured by Actavis Pharma, Inc.
46,840 FDA adverse event reports analyzed
Last updated: 2026-04-14
OXAZEPAM is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Actavis Pharma, Inc.. The most commonly reported adverse reactions for OXAZEPAM include TOXICITY TO VARIOUS AGENTS, FALL, DRUG ABUSE, HYPOTENSION, DRUG INTERACTION. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for OXAZEPAM.
Out of 20,328 classified reports for OXAZEPAM:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.